Analysis of the Molecular Composition of Tubal Cilia in Patients With or Without Ectopic Pregnancy

NCT ID: NCT05374720

Last Updated: 2023-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Ciliary Dyskinesia associated with abnormalities of lateralization of organs (with existence of a situs inversus in 50% of cases) and secondary fertility disorders related in humans to abnormalities of mobility of sperm but very little data on the structure and function of tubal cilia in women

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Ciliary Dyskinesia (DCP) is a rare genetic disease (1 in 15,000 individuals at birth), which manifests itself in chronic respiratory infections (bronchopneumopathies and rhinosinusitis type) associated with abnormalities of lateralization of organs (with existence of a situs inversus in 50% of cases) and secondary fertility disorders related in humans to abnormalities of sperm mobility. However, there is very little data in the literature on the structure and function of tubal cilia in women with DCP.

Before considering a study of tubal cilia in patients with DCP, it seems necessary to specify in DCP patients or not DCP, the molecular and morphological composition of tubal cilia and to look for ciliary abnormalities in case of GEU

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Salpingectomy Hysterectomy Primary Ciliary Dyskinesia Ectopic Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Salpingectomy for Extra-Uterine Pregnancy

patients with salpingectomy for Ectopic Pregnancy

Group Type EXPERIMENTAL

salpingectomy

Intervention Type PROCEDURE

Removal of one of the fallopian tubes.

hysterectomies

patients with hysterectomy for prolapsus, adenomyosis or myomectomy

Group Type SHAM_COMPARATOR

hysterectomy

Intervention Type PROCEDURE

remove the uterus, whole or only part. It may also involve the removal of the cervix, ovaries, fallopian tubes and other surrounding structures.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

salpingectomy

Removal of one of the fallopian tubes.

Intervention Type PROCEDURE

hysterectomy

remove the uterus, whole or only part. It may also involve the removal of the cervix, ovaries, fallopian tubes and other surrounding structures.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with scheduled salpingectomy (Ectopic pregnancy, hysterectomy for prolapsus, adenomyosis or myomectomy)
* Major patients ( \>18 years)

Exclusion Criteria

* Patient not willing to participate in the study
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Intercommunal Creteil

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rana i MITRI-FRANGIEH

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier Intercommunal Créteil

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Intercommunal Créteil

Créteil, Val-deMarne, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rana MITRI- FRANGIEH

Role: CONTACT

+33 01 57 02 22 86

Camille Jung

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Rana i MITRI-FRANGIEH

Role: primary

+33157022286

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CILTUBE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.